Come on finish $5 plus, page-38

from AFR:
an upcoming ASX IPO company Triad Life Sciences was valued at $500m but the IPO plan was halted because its board is considering a takeover bid with 30% premium, giving the company an implied value of $650m.

taking an extremely conservative approach, assuming ARX is same as Triad, this alone will give ARX a sp of above $1.9 and moreover:

I have checked Triad website and find limited info (I personally feel much of it just bluffing and lack of substantiation). have a look urself.

my understanding is Triad, as a later comer, has not (or just planned to) commercialize its product, whist ARX has a range of commercialize products with proven effectiveness, a deployed and active sales team, distribution contracts with reputable distribution network, high gross margin, stable royalties, no debts and no capital raising on the road to profitability.

I do think ARX cap should be much higher than $650m valuation given to Triad. I think ARX is a hidden gem sooner or later to be found by more investors.

DYOR AND GLTA.